Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BICE vs ICE in Relapsed/Refractory Classical Hodgkin Lymphoma
NCT00967369Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2009
- Primary completion
- May 2018
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in classical Hodgkin lymphoma (cHL), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2009; status: completed.
02
Drugs
bortezomib
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT00967369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00967369.